Search research articles
Contact Us
Filters
Showing results (121-130 of 135) with videos related to
Page
of 14
Sort By:
The Journal of Allergy and Clinical Immunology
|
January 24, 2026
Bimekizumab long-term response in psoriasis: Mechanistic insights into efficacy level and durability
James G Krueger, Ioana Cutcutache, Mark Lebwohl, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
May 23, 2026
Durability of response to icotrokinra for high-impact site psoriasis: 1-year ICONIC-TOTAL findings
Richard B Warren, Melinda Gooderham, Edward Lain, et al.
The New England Journal of Medicine
|
November 5, 2025
Oral Icotrokinra for Plaque Psoriasis in Adults and Adolescents
Robert Bissonnette, Jennifer Soung, Adelaide A Hebert, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
December 12, 2023
Sex differences in adverse events from systemic treatments for psoriasis: A decade of insights from the Swiss Psoriasis Registry (SDNTT)
Fabio Verardi, Lara Valeska Maul, Kim Borsky, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
May 21, 2024
S2k guideline for the treatment of hidradenitis suppurativa / acne inversa - Short version
Christos C Zouboulis, Falk G Bechara, Klaus Fritz, et al.
JAMA Dermatology
|
July 31, 2024
Noninferiority of 16-Week vs 8-Week Guselkumab Dosing in Super Responders for Maintaining Control of Psoriasis: The GUIDE Randomized Clinical Trial
Kilian Eyerich, Khusru Asadullah, Andreas Pinter, et al.
Skin Health and Disease
|
November 28, 2025
Large Eczema Area and Severity Index response at 2-year follow-up of patients treated with dupilumab in routine care of atopic dermatitis: results from the national registry TREATgermany
Luise Heinrich, Thomas Birkner, Susanne Abraham, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
March 28, 2024
Treatment of moderate-to-severe atopic dermatitis with baricitinib: Results from an interim analysis of the TREATgermany registry
Stephan Traidl, Luise Heinrich, Doreen Siegels, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
April 25, 2024
Obesity is linked to disease severity in moderate to severe atopic dermatitis-Data from the prospective observational TREATgermany registry
Stephan Traidl, Moritz M Hollstein, Nadine Kroeger, et al.
The British Journal of Dermatology
|
October 13, 2025
Vilobelimab to improve clinical outcomes of moderate-to-severe hidradenitis suppurativa through an adjunctive effect on draining tunnels: Results of the SHINE double-blind, placebo-controlled randomised trial
Evangelos J Giamarellos-Bourboulis, Gregor B E Jemec, Errol P Prens, et al.
Page
of 14
Search research articles
Search
Showing results (121-130 of 135) with videos related to
Sort By:
Page
of 14
The Journal of Allergy and Clinical Immunology
|
January 24, 2026
Bimekizumab long-term response in psoriasis: Mechanistic insights into efficacy level and durability
James G Krueger, Ioana Cutcutache, Mark Lebwohl, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
May 23, 2026
Durability of response to icotrokinra for high-impact site psoriasis: 1-year ICONIC-TOTAL findings
Richard B Warren, Melinda Gooderham, Edward Lain, et al.
The New England Journal of Medicine
|
November 5, 2025
Oral Icotrokinra for Plaque Psoriasis in Adults and Adolescents
Robert Bissonnette, Jennifer Soung, Adelaide A Hebert, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
December 12, 2023
Sex differences in adverse events from systemic treatments for psoriasis: A decade of insights from the Swiss Psoriasis Registry (SDNTT)
Fabio Verardi, Lara Valeska Maul, Kim Borsky, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
May 21, 2024
S2k guideline for the treatment of hidradenitis suppurativa / acne inversa - Short version
Christos C Zouboulis, Falk G Bechara, Klaus Fritz, et al.
JAMA Dermatology
|
July 31, 2024
Noninferiority of 16-Week vs 8-Week Guselkumab Dosing in Super Responders for Maintaining Control of Psoriasis: The GUIDE Randomized Clinical Trial
Kilian Eyerich, Khusru Asadullah, Andreas Pinter, et al.
Skin Health and Disease
|
November 28, 2025
Large Eczema Area and Severity Index response at 2-year follow-up of patients treated with dupilumab in routine care of atopic dermatitis: results from the national registry TREATgermany
Luise Heinrich, Thomas Birkner, Susanne Abraham, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
March 28, 2024
Treatment of moderate-to-severe atopic dermatitis with baricitinib: Results from an interim analysis of the TREATgermany registry
Stephan Traidl, Luise Heinrich, Doreen Siegels, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
April 25, 2024
Obesity is linked to disease severity in moderate to severe atopic dermatitis-Data from the prospective observational TREATgermany registry
Stephan Traidl, Moritz M Hollstein, Nadine Kroeger, et al.
The British Journal of Dermatology
|
October 13, 2025
Vilobelimab to improve clinical outcomes of moderate-to-severe hidradenitis suppurativa through an adjunctive effect on draining tunnels: Results of the SHINE double-blind, placebo-controlled randomised trial
Evangelos J Giamarellos-Bourboulis, Gregor B E Jemec, Errol P Prens, et al.
Page
of 14